ATRA:NSD-Atara Biotherapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.99

Change

0.00 (0.00)%

Market Cap

USD 1.26B

Volume

0.65M

Avg Analyst Target

USD 31.50 (+125.16%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Atara Biotherapeutics Inc (ATRA) Stock Analysis:
Based on the Atara Biotherapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Atara Biotherapeutics Inc is USD 31.50 over the next 12 months. Atara Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Atara Biotherapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Atara Biotherapeutics Inc’s stock price was USD 13.99. Atara Biotherapeutics Inc’s stock price has changed by -2.08% over the past week, -3.32% over the past month and -24.13% over the last year.

About

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

USD25.75B N/A N/A
SGEN Seagen Inc

N/A

USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

USD16.81B 20.32 11.89

ETFs Containing ATRA

Symbol Name Weight Mer Price(Change) Market Cap
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.23% 71% C- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.23% 71% C- 41% F
Trailing 12 Months  
Capital Gain -24.13% 79% C+ 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.13% 79% C+ 38% F
Trailing 5 Years  
Capital Gain 1.75% 59% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.75% 59% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain 27.65% 64% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.65% 64% D 74% C
Risk Return Profile  
Volatility (Standard Deviation) 86.01% 34% F 19% F
Risk Adjusted Return 32.15% 63% D 50% F
Market Capitalization 1.26B 84% B 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.63 29% F 27% F
Price / Cash Flow Ratio -6.96 61% D- 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -98.81% 28% F 12% F
Return on Invested Capital -82.08% 26% F 10% F
Return on Assets -48.04% 14% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.44 7% F 4% F
Short Percent 11.99% 13% F 14% F
Beta 1.86 20% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector